Tau is reduced in AD plasma and validation of employed ELISA methods.

Abstract

The data suggest that changes in circulating tau levels quantified in plasma samples, but not serum samples, may represent a viable biomarker for tracking the progression of AD and the efficacy of medications in its treatment.